These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33837851)

  • 1. Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program.
    Arranz-Nicolás J; Martin-Salgado M; Adán-Barrientos I; Liébana R; Del Carmen Moreno-Ortíz M; Leitner J; Steinberger P; Ávila-Flores A; Merida I
    Cancer Immunol Immunother; 2021 Nov; 70(11):3277-3289. PubMed ID: 33837851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes.
    Arranz-Nicolás J; Martin-Salgado M; Rodríguez-Rodríguez C; Liébana R; Moreno-Ortiz MC; Leitner J; Steinberger P; Ávila-Flores A; Merida I
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33246984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals.
    Arranz-Nicolás J; Ogando J; Soutar D; Arcos-Pérez R; Meraviglia-Crivelli D; Mañes S; Mérida I; Ávila-Flores A
    Cancer Immunol Immunother; 2018 Jun; 67(6):965-980. PubMed ID: 29572701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diacylglycerol kinases in cancer.
    Mérida I; Torres-Ayuso P; Ávila-Flores A; Arranz-Nicolás J; Andrada E; Tello-Lafoz M; Liébana R; Arcos R
    Adv Biol Regul; 2017 Jan; 63():22-31. PubMed ID: 27697466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy for hepatocellular carcinoma with diacylglycerol kinase alpha inhibition and anti-programmed cell death-1 ligand blockade.
    Okada N; Sugiyama K; Shichi S; Shirai Y; Goto K; Sakane F; Kitamura H; Taketomi A
    Cancer Immunol Immunother; 2022 Apr; 71(4):889-903. PubMed ID: 34482409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.
    Riese MJ; Wang LC; Moon EK; Joshi RP; Ranganathan A; June CH; Koretzky GA; Albelda SM
    Cancer Res; 2013 Jun; 73(12):3566-77. PubMed ID: 23576561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity.
    Wichroski M; Benci J; Liu SQ; Chupak L; Fang J; Cao C; Wang C; Onorato J; Qiu H; Shan Y; Banas D; Powles R; Locke G; Witt A; Stromko C; Qi H; Zheng X; Martin S; Ding M; Gentles R; Meanwell N; Velaparthi U; Olson R; Wee S; Tenney D; Parker CG; Cravatt BF; Lawrence M; Borzilleri R; Lees E
    Sci Transl Med; 2023 Oct; 15(719):eadh1892. PubMed ID: 37878674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diacylglycerol Kinase ζ Limits Cytokine-dependent Expansion of CD8
    Andrada E; Liébana R; Merida I
    EBioMedicine; 2017 May; 19():39-48. PubMed ID: 28438506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
    Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
    Front Immunol; 2021; 12():737076. PubMed ID: 34659228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Combination of Anti-PD-L1 Treatment and Therapeutic Vaccination Facilitates Improved Retroviral Clearance via Reactivation of Highly Exhausted T Cells.
    Knuschke T; Kollenda S; Wenzek C; Zelinskyy G; Steinbach P; Dittmer U; Buer J; Epple M; Westendorf AM
    mBio; 2021 Feb; 12(1):. PubMed ID: 33531395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of diacylglycerol kinase α restores restimulation-induced cell death and reduces immunopathology in XLP-1.
    Ruffo E; Malacarne V; Larsen SE; Das R; Patrussi L; Wülfing C; Biskup C; Kapnick SM; Verbist K; Tedrick P; Schwartzberg PL; Baldari CT; Rubio I; Nichols KE; Snow AL; Baldanzi G; Graziani A
    Sci Transl Med; 2016 Jan; 8(321):321ra7. PubMed ID: 26764158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer.
    Purow B
    Clin Cancer Res; 2015 Nov; 21(22):5008-12. PubMed ID: 26420856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel diacylglycerol kinase α-selective inhibitor, CU-3, induces cancer cell apoptosis and enhances immune response.
    Liu K; Kunii N; Sakuma M; Yamaki A; Mizuno S; Sato M; Sakai H; Kado S; Kumagai K; Kojima H; Okabe T; Nagano T; Shirai Y; Sakane F
    J Lipid Res; 2016 Mar; 57(3):368-79. PubMed ID: 26768655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.